Decibel Therapeutics Appoints Dr William H Carson as Chairman of the Board of Directors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
®, the first FDA-approved digital medicine.
Bill currently serves as Chairman of the Board of Directors of OPDC and is also the Chairman of the Board of the Sozosei Foundation, a newly established Otsuka charitable organization focused on decriminalization of mental illness. He serves on the boards of Excision BioTherapeutics, Saama and Annexon Biosciences and is Trustee of the non-profit Internet2. He is Board Chair Emeritus of the Sphinx Organization, which advocates for parity and inclusion in the arts.
“Bill is an eminent figure in the biopharmaceutical community with a proven track record of advancing therapies through clinical development, regulatory approval and commercialization. His appointment demonstrates our ambition to establish Decibel at the forefront of innovation in treatments to restore and improve hearing and balance,” said Laurence Reid, Ph.D., Chief Executive Officer. “Bill is passionate about delivering life-changing therapies in areas of unmet medical
Collaboration to discover and evaluate novel product concepts based on the combination of Genmab's antibodies and bispecific antibody technologies with Bolt's proprietary immune-stimulating antibody
Bolsters team with addition of established biopharma industry leaders in advance of anticipated regulatory approval and commercialization of once-nightly.
Confirm
Bolsters team with addition of established biopharma industry leaders in advance of anticipated regulatory approval and commercialization of once-nightly FT218 for narcolepsy
DUBLIN, Ireland, June 02, 2021 (GLOBE NEWSWIRE) Avadel Pharmaceuticals plc ( AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today it has appointed Jeff Cruikshank as Vice President, Sales; Denise Strauss as Vice President, Marketing and New Product Strategy; and Angela Woods as Vice President, People and Culture.
These newly-created roles will continue to build the Company’s capabilities to support the potential approval and commercialization of once-nightly FT218. As Vice President, Sales, Mr. Cruikshank will lead the development of Avadel’s go-to-market customer model including the buildout and deployment of the Company’s patient-focused